Back to Search Start Over

Colony‐stimulating factor‐1 receptor inhibition attenuates microgliosis and myelin loss but exacerbates neurodegeneration in the chronic cuprizone model

Authors :
Victoria S. B. Wies Mancini
Anabella A. Di Pietro
Soledad Olmos
Pablo Silva Pinto
Marianela Vence
Mariel Marder
Lionel M. Igaz
María S. Marcora
Juana M. Pasquini
Jorge D. Correale
Laura A. Pasquini
Source :
Journal of Neurochemistry. 160:643-661
Publication Year :
2022
Publisher :
Wiley, 2022.

Abstract

Multiple sclerosis (MS), especially in its progressive phase, involves early axonal and neuronal damage resulting from a combination of inflammatory mediators, demyelination, and loss of trophic support. During progressive disease stages, a microenvironment is created within the central nervous system (CNS) favoring the arrival and retention of inflammatory cells. Active demyelination and neurodegeneration have also been linked to microglia (MG) and astrocyte (AST)-activation in early lesions. While reactive MG can damage tissue, exacerbate deleterious effects, and contribute to neurodegeneration, it should be noted that activated MG possess neuroprotective functions as well, including debris phagocytosis and growth factor secretion. The progressive form of MS can be modeled by the prolonged administration to cuprizone (CPZ) in adult mice, as CPZ induces highly reproducible demyelination of different brain regions through oligodendrocyte (OLG) apoptosis, accompanied by MG and AST activation and axonal damage. Therefore, our goal was to evaluate the effects of a reduction in microglial activation through orally administered brain-penetrant colony-stimulating factor-1 receptor (CSF-1R) inhibitor BLZ945 (BLZ) on neurodegeneration and its correlation with demyelination, astroglial activation, and behavior in a chronic CPZ-induced demyelination model. Our results show that BLZ treatment successfully reduced the microglial population and myelin loss. However, no correlation was found between myelin preservation and neurodegeneration, as axonal degeneration was more prominent upon BLZ treatment. Concomitantly, BLZ failed to significantly offset CPZ-induced astroglial activation and behavioral alterations. These results should be taken into account when proposing the modulation of microglial activation in the design of therapies relevant for demyelinating diseases. Cover Image for this issue: https://doi.org/10.1111/jnc.15394.

Details

ISSN :
14714159 and 00223042
Volume :
160
Database :
OpenAIRE
Journal :
Journal of Neurochemistry
Accession number :
edsair.doi.dedup.....cfca4c7232d3a2a850f315a30fb8d9d1
Full Text :
https://doi.org/10.1111/jnc.15566